Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide
Journal of Cardiovascular Development and Disease · 17.11.2023 · 10 (11) · 468
DOI: 10.3390/jcdd10110468 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 17.11.2023. Verfasst von Mauro Riccardi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Un…. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Soluble (s)ST2 has been proposed as a useful biomarker for heart failure (HF) patient management. Myocardial damage or mechanical stress stimulate sST2 release. ST2 competes with a membrane bound receptor (ST2 ligand, or ST2L) for interleukin-33 (IL-33) binding, inhibiting the effects induced by the ST2L/IL-33 interaction so that excessive sST2 may contribute to myocardial fibrosis and ventricular remodeling. Compared to natriuretic peptides (NPs), sST2 concentration is not substantially affected by age, sex, body mass index, kidney function, atrial fibrillation, anemia, or HF etiology, and has low intra-individual variation. Its prognostic role as an independent marker is well reported in the literature. However, there is a gap on its use in combination with NPs, currently the only biomarkers recommended by European and American guidelines for HF management. Reflecting the activation of two distinct biological systems, a benefit from the use of sST2 and NP in combination is advocated. The aim of this review is to report the current scientific knowledge on sST2 in the acute and chronic HF settings with a particular attention to its additive role to natriuretic peptides (NPs).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, 25121 Brescia, Italy.
- Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, 1478 Nordbyhagen, Norway.
- K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, University of Oslo, 0313 Oslo, Norway.
- Department of Internal Medicine II, Division of Cardiology, Center of Cardiovascular Medicine, Medical University of Vienna, 1090 Vienna, Austria.
- Cardiology Division, Massachusetts General Hospital, Harvard Medical School, and Baim Institute for Clinical Research, Boston, MA 02215, USA.
ORCID-Profile: Peder L Myhre, Thomas A Zelniker, Riccardo M Inciardi
Zitieren
APA
Riccardi, M., Myhre, P. L., Zelniker, T. A., Metra, M., Januzzi, J. L., & Inciardi, R. M. (2023). Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease, 10(11), 468. https://doi.org/10.3390/jcdd10110468
Vancouver
Riccardi M, Myhre PL, Zelniker TA, Metra M, Januzzi JL, Inciardi RM. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease. 2023;10(11):468. doi:10.3390/jcdd10110468
BibTeX
@article{Riccardi2023,
author = {Riccardi, Mauro and Myhre, Peder L and Zelniker, Thomas A and Metra, Marco and Januzzi, James L and Inciardi, Riccardo M},
title = {Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide},
journal = {Journal of Cardiovascular Development and Disease},
year = {2023},
volume = {10},
number = {11},
pages = {468},
doi = {10.3390/jcdd10110468}
}
EUVIMED